News

Yahoo Finance7mon

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 ...
Taiwan News9mon

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ALX ...
Morningstar6mon

ALX Oncology to Host Virtual R&D Day on March 5, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies ...
Business Wire5y

ALX Oncology to Present ALX148 Phase 1 Clinical Data at the Virtual 25 th Congress of the European Hematology Association (EHA)

BURLINGAME, Calif.--(BUSINESS WIRE)--ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the Phase 1 ...